Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.44 |
| ▸ | FYN | P06241 | 3/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4865064 | 1.00 | BRAF (0.44) | BRAFFYNKITGSK3BPIK3C3 | |
| SCHEMBL4862413 | 0.87 | KIT (0.41) | BRAFFYNKITPIK3C3MAPT | |
| SCHEMBL4862409 | 0.87 | KIT (0.41) | BRAFFYNKITPIK3C3MAPT | |
| SCHEMBL4865283 | 0.87 | BRD4 (0.39) | MAPTADORA3 | |
| SCHEMBL4865287 | 0.87 | BRD4 (0.39) | MAPTADORA3 | |
| SCHEMBL4855994 | 0.86 | FYN (0.42) | FYNKITMAPT | |
| SCHEMBL4855988 | 0.86 | FYN (0.42) | FYNKITMAPT | |
| SCHEMBL4864178 | 0.85 | EGFR (0.43) | BRAFSMN1; SMN2 | |
| SCHEMBL4864163 | 0.85 | EGFR (0.43) | BRAFSMN1; SMN2 | |
| SCHEMBL4862410 | 0.85 | MAPT (0.38) | BRAFFYNGSK3BMAPTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452873-B2 | Inhibitors of GSK-3 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-18 | — | — | US | disclosed |
| US-20050222237-A1 | Inhibitors of GSK-3 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2005-10-06 | — | — | US | disclosed |
| US-6916798-B2 | Inhibitors of GSK-3 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-07-12 | — | — | US | disclosed |
| US-20040024040-A1 | Inhibitors of GSK-3 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024040-A1 | Inhibitors of GSK-3 and uses thereof | GSK3B, AURKC, GSK3A | BRAF 825/4885FYN 1415/4885KIT 847/4885 |
| US-20050222237-A1 | Inhibitors of GSK-3 and uses thereof | GSK3B, AURKC, GSK3A | BRAF 825/4885FYN 1415/4885KIT 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.